Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Loss of Tumor Suppressor Gene Functions

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...

Cancer-Critical Genes II: Tumor Suppressor Genes

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

Mismatch Repair

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Corrigendum to "Recurrent Transcriptional Responses in AML and MDS patients Treated with Decitabine" Experimental Hematology. 2022;111:50-65.

Experimental hematology·2026

Same author

Synthetic lethality of decitabine plus ATR inhibition for TP53-mutated AML.

Blood advances·2026

Same author

Evaluation of Long-Read Genome Sequencing for Genomic Profiling of Myeloid Cancers.

The Journal of molecular diagnostics : JMD·2025

Same author

A clinical guide to TP53 mutations in myeloid neoplasms.

Blood·2025

Same author

Germline genetic variation impacts clonal hematopoiesis landscape and progression to malignancy.

Nature genetics·2025

Same author

How chemotherapy shapes hematopoietic stem cells.

Nature genetics·2025

Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025

Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025

Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025

Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025

Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025

Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 5, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Are TP53 mutations all alike?

Terrence N Wong¹, Daniel C Link²

¹Division of Hematology-Oncology, University of Michigan, Ann Arbor, MI.

Hematology. American Society of Hematology. Education Program

|December 7, 2024

Summary

This summary is machine-generated.

TP53 mutations are common in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), impacting patient prognosis. Multihit TP53 mutations, particularly hot-spot mutations, are linked to poor outcomes and require specific genetic testing for management.

More Related Videos

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology

Published on: March 21, 2018

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Related Experiment Videos

Last Updated: Jun 5, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology

Published on: March 21, 2018

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Area of Science:

Hematology
Oncology
Molecular Biology

Background:

TP53 mutations occur in 10-15% of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) cases.
These mutations are associated with prior cytotoxic therapy, complex cytogenetics, and poor prognosis.
TP53-mutant allele status is crucial and necessitates specific genetic testing.

Purpose of the Study:

To review evidence on TP53 mutations in AML/MDS.
To discuss the impact of TP53 mutation status on patient outcomes.
To explore potential clinical management strategies for TP53-mutant AML/MDS.

Main Methods:

Literature review of existing data on TP53 mutations in AML/MDS.
Analysis of TP53-mutant allele status and its correlation with clinical features.
Examination of mutation types, including hot-spot mutations in the DNA binding domain.

Main Results:

Multihit TP53-mutant AML/MDS shows increased chromosomal abnormalities and reduced overall survival compared to monoallelic disease.
Most TP53 mutations are missense mutations within the DNA binding domain.
Hot-spot mutations (R175, Y220, G245, R248, R273, R282) constitute about 35% of TP53 missense mutations in AML/MDS.

Conclusions:

TP53 hot-spot mutations may exhibit dominant-negative or gain-of-function properties.
Understanding TP53 mutation status is vital for predicting patient outcomes in AML/MDS.
This knowledge can inform clinical management and therapeutic decisions for affected patients.